News roundup Monday, November 11

secures loan financing of at least SEK 250 million to reach set milestones by 2026. Read more.

Curasight announces brain cancer as the first indication for uTREAT. Read more.

Faron Pharmaceuticals has filed a patent application regarding Clever-1. Read more.

Cyxone receives payment demands of just under SEK 5 million. Read more.

ALK licenses the rights to the adrenaline spray neffy. Read more.

Patient data from the extension part of Alzinova's Phase Ib study with ALZ-101 is in progress. Read more.

The useful life of CLS warrants of series TO 7 B begin today. Read more.

A3P Biomedical launches Stockholm3 in Germany. Read more.

CS MEDICA is expanding its presence in Eastern Europe through a new partnership. Read more.

NextCell Pharma announces that the subsidiary QVance publishes article on particles in cell and gene therapy products in collaboration with ISCT. Read more.

Cantargia announces that results for CAN10 in models of myocardial inflammation are published in Circulation: Heart Failure. Read more.

BioPorto sponsors exhibitions in connection with the launch of ProNephro AKI in the USA. Read more.

Medistim announces the launch of the MiraQ INTUI software platform. Read moreThe company will hold a capital markets day on December 16, 2024. Read more.

Monivents Chairman of the Board resigns. Read more.

Diagonal Bio announces that it is investigating financing options. Read more.

Qlife publishes outcomes in private placements. Read more.

Today the subscription period begins in Spermosis Rights issue of units. Read more.

AcuCort postpones the date for publication of the interim report for the third quarter. Read more.